Clinical development of biologicals and biosimilars - safety concerns
Open Access
- 17 April 2017
- journal article
- editorial
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 10 (6) , 567-569
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety, 2016
- Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety, 2016
- Biosimilars in IBD: from theory to practiceNature Reviews Gastroenterology & Hepatology, 2016
- Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysisClinical Gastroenterology and Hepatology, 2016
- Biosimilars: A consideration of the regulations in the United States and European unionRegulatory Toxicology and Pharmacology, 2016
- Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyArthritis Research & Therapy, 2016
- Biologic agents for IBD: practical insightsNature Reviews Gastroenterology & Hepatology, 2015
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Biosimilar therapeutics--what do we need to consider?NDT Plus, 2009